Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,287
datasets available to search
ShareScore release 0.9.0
Dataset results
5,287 results for “colorectal cancer”
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
ClinicalTrials.gov study NCT03362177. IPD Sharing: YES. Countries: 20. Publications: 0.
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
ClinicalTrials.gov study NCT03007407. IPD Sharing: Not stated. Countries: 1. Publications: 1.
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
ClinicalTrials.gov study NCT02861300. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Reducing Colorectal Cancer Death Through Mailed Outreach Screening
ClinicalTrials.gov study NCT02584998. IPD Sharing: NO. Countries: 1. Publications: 1.
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
ClinicalTrials.gov study NCT00125034. IPD Sharing: Not stated. Countries: 13. Publications: 2.
A Study in Second Line Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT01183780. IPD Sharing: YES. Countries: 26. Publications: 8.
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
ClinicalTrials.gov study NCT03829462. IPD Sharing: YES. Countries: 1. Publications: 4.
Colorectal cancer interleukin-10 blockade scRNA-seq
Open the record for dataset details and reuse information.
Data from: Uranium and Radium in groundwater and incidence of colorectal cancer in Georgia counties, USA: An ecologic study
Open the record for dataset details and reuse information.
Data from: Novel methods to define invasive procedures at the end-of-life were developed to improve quality of end of life care research: A population-based cohort study in colorectal cancer
Open the record for dataset details and reuse information.
Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatment
Open the record for dataset details and reuse information.
Colorectal cancer scRNA-seq 10xG-format data matrix
Open the record for dataset details and reuse information.
Liver regeneration-associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competition
Open the record for dataset details and reuse information.
Data for " SCTR hypermethylation is a diagnostic biomarker in colorectal cancer"
<p>This data set provides data files to accompany the article SCTR hypermethylation is a diagnostic biomarker in colorectal cancer.</p> <p>The data consists of methylation profiles of SCTR gene from The Cancer Genome Atlas (TCGA) CRC methylation data (N = 440), a large-scale test set (N = 938) from the Gene Expression Omnibus (GEO), and our independent validation set (N = 371).</p>
Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50 to 70 years: A qualitative study
<span>Objectives</span> <p>Australian guidelines recommend all 50 to 70-year-olds without existing contraindications consider taking low-dose aspirin (100 mg – 300 mg per day) for at least 2.5 years to reduce their risk of developing colorectal cancer.</p> <p>We aimed to explore clinicians', practices, knowledge, opinions, and barriers and facilitators to the implementation of these new guidelines.</p> <span>Methods</span> <p>Semi-structured interviews were conducted with clinicians to whom the new guidelines may be applicable (familial cancer clinic staff (geneticists, oncologists and genetic counsellors), gastroenterologists, pharmacists, and general practitioners (GPs)).</p> <p>The Consolidated Framework for Implementation Research (CFIR) underpinned the development of the interview guide. Coding was inductive and themes were developed through consensus between the authors.</p> <p>Emerging themes were mapped onto the CFIR domains: characteristics of the intervention, outer setting, inner setting, individual characteristics and process.</p> <span>Results </span> <p>Sixty-four interviews were completed between March and October 2019. Aspirin was viewed as a safe and cheap option for cancer prevention. GPs were considered by all clinicians as the most important health professionals for implementation of the guidelines. Cancer Council Australia, as a trusted organisation, was an important facilitator to guideline adoption. Uncertainty about aspirin dosage and perceived strength of the evidence, the precise wording of the recommendation, previous changes to guidelines about aspirin, and conflicting findings from trials in older populations were barriers to implementation.</p> <span>Conclusion</span> <p>Widespread adoption of these new guidelines could be an important strategy to reduce the incidence of bowel cancer, but this will require more active implementation strategies focused on primary care and the wider community.</p>
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial
<p><b>Objectives</b> Cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomized, multicentre, phase III trial. Nevertheless, the cost-effectiveness of these two regimens remains uncertain. The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective strategy for specific RAS wt mCRC patients in China.</p> <p><b>Design</b> A combined decision tree and Markov model with three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with RAS wt mCRC. The health outcomes and utility scores were derived from the TAILOR trial and previously published sources, respectively. Costs were calculated with reference to the Chinese societal perspective. A lifetime horizon was used. Univariate and probabilistic sensitivity analyses were carried out to test the robustness of the model results.</p> <p><b>Participants</b> The included patients were newly diagnosed Chinese patients with fully RAS wt mCRC. <b>Interventions</b> Either cetuximab plus FOLFOX-4 or FOLFOX-4 alone as a first-line treatment.</p> <p><b>Main outcome measures</b> The primary outcomes are costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).</p> <p><b>Results</b> Baseline analysis showed that the addition of cetuximab increased the QALYs by 0.383, while an increase of $62,947 was observed in relation to FOLFOX-4 chemotherapy. This led to an incremental cost-effectiveness ratio (ICER) of $164,044/QALY. Sensitivity analysis showed that across the wide variation in parameters, the ICER exceeded the willingness-to-pay threshold of $28,106/QALY, which was three times the per capita GDP in China.</p> <p><b>Conclusions</b> Despite the survival benefit, cetuximab combined with FOLFOX-4 is not a cost-effective treatment for the first line treatment of patients with RAS wt mCRC in China.</p>
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics: fastq & bam files - Sample S5_Rec
<p>You can find here the fastq and bam files related to the datasets used in the publication: </p> <p>In this particular upload, you can find the fastq (version1) and bam (version2) files of the two replicates of sample S5_Rec (A121573)</p> <p><strong>Valdeolivas, A., Amberg, B., Giroud, N. <em>et al.</em> Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics. <em>npj Precis. Onc.</em> 8, 10 (2024). https://doi.org/10.1038/s41698-023-00488-4</strong></p> <p> </p> <p> </p>
Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance.
Open the record for dataset details and reuse information.
The single-cell spatial landscape of stage III colorectal cancers
<p>We added H&E images with pathologist annotations in this version (v2). All other files are available in version 1. </p> <p> </p> <p>The Seurat and Scanpy objects for single-cell data, along with a CSV file containing coordinates and cell types for all single cells, have been deposited. Additionally, the original IMC image data has also been uploaded.</p> <p>The Seurat object is: <em>20220215_COAD_cancer_control_umapped_annotated<strong>.rds</strong></em></p> <p>The Scanpy object is: <em>20220215_COAD_cancer_control_umapped_annotated.<strong>h5ad</strong></em></p> <p> </p>
Parameters for "Planning for the next pandemic: The Finnish colorectal cancer screening programme"
<p>Parameters used in the pape "Planning for the next pandemic: The Finnish colorectal cancer screening programme" </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.